Harmony Biosciences Holdings (HRMY) — Cash Flow Quality Index
Harmony Biosciences Holdings (HRMY) has a Cash Flow Quality Index of 2.14x as of September 2025. Operating cash flow of $108.73 Million exceeds net income of $50.87 Million, indicating high earnings quality where cash backs reported profits. Explore HRMY long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Harmony Biosciences Holdings Cash Flow Quality Index (2021–2024)
Historical Cash Flow Quality Index for Harmony Biosciences Holdings across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check HRMY tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Harmony Biosciences Holdings (2021–2024)
Year-by-year earnings quality comparison for Harmony Biosciences Holdings. For live market cap and the full company financial profile, see HRMY company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.51x | $219.82 Million | $145.49 Million | ▼ -11.3% |
| 2023 | 1.70x | $219.39 Million | $128.85 Million | ▲ +113.9% |
| 2022 | 0.80x | $144.47 Million | $181.47 Million | ▼ -72.1% |
| 2021 | 2.85x | $98.56 Million | $34.60 Million | — |